Quantifying factors for the success of stratified medicine.
Co-developing a drug with a diagnostic to create a stratified medicine - a therapy that is targeted to a specific patient population on the basis of a clinical characteristic such as a biomarker that predicts treatment response - presents challenges for product developers, regulators, payers and physicians. With the aim of developing a shared framework and tools for addressing these challenges, here we present an analysis using data from case studies in oncology and Alzheimer's disease, coupled with integrated computational modelling of clinical outcomes and developer economic value, to quantify the effects of decisions related to key issues such as the design of clinical trials. This illustrates how such analyses can aid the coordination of diagnostic and drug development, and the selection of optimal development and commercialization strategies. It also illustrates the impact of the interplay of these factors on the economic feasibility of stratified medicine, which has important implications for public policy makers.
Massachusetts Institute of Technology, Sloan School of Management and Center for Biomedical Innovation, 100 Main Street, Cambridge, Massachusetts 02139, USA. Trusheim@mit.edu
Mark R
MR
Trusheim
Breon
B
Burgess
Sean Xinghua
SX
Hu
Theresa
T
Long
Steven D
SD
Averbuch
Aiden A
AA
Flynn
Alfons
A
Lieftucht
Abhijit
A
Mazumder
Judy
J
Milloy
Peter M
PM
Shaw
David
D
Swank
Jian
J
Wang
Ernst R
ER
Berndt
Federico
F
Goodsaid
Michael C
MC
Palmer
D000544:Alzheimer Disease / Q000453:epidemiology / Q000628:therapy; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000639:trends; D019295:Computational Biology / Q000379:methods* / Q000639:trends; D006801:Humans; D008511:Medicine / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000453:epidemiology / Q000628:therapy; D012107:Research Design / Q000639:trends